| Date | Title | Description |
| 17.08.2026 | Leal Therapeutics Raises $30M in Second Close of Series A Funding | Leal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding.
Backers included Eli Lilly and Company, OrbiMed, Newpath Partne... |
| 30.07.2026 | ADQ-anchored Lunate, Orbimed, Creaegis invest in Indian healthcare firm | Premium
Credit: Freepik
A host of domestic and foreign institutional investors including private equity firms and pension funds are betting on a......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a se... |
| 18.07.2026 | TytoCare Bolsters Leadership, Secures $25M+ for AI-First Chronic Care | TytoCare secures over $25 million in growth financing. Adam Pellegrini joins as CEO. Greg Orr becomes COO. This investment fuels a major strategic pivot. TytoCare now targets high-acuity chronic conditions. Its FDA-cleared handheld device c... |
| 17.07.2026 | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.
Fri, Jul 17, 2026 08:00 CET Report this content
17 July 2026
THE BIOTECH GROWTH TRUST PLC
(“BIOG” or the "Company")
Eli Lilly to acquire BIOG portfolio company, AtaiBec... |
| 16.07.2026 | TytoCare Secures $25M and Appoints Adam Pellegrini as CEO | Adam Pellegrini, CEO at TytoCare What You Should Know
Telehealth innovator TytoCare has announced a $25 million-plus growth financing round alongside the high-profile appointment of digital health veteran Adam Pellegrini as Chief Executive ... |
| 15.07.2026 | TytoCare Names Adam Pellegrini As CEO And Closes $25+ Million Growth Round To Scale AI-First Clinical Enablement Platform | TytoCare, pioneer of remote physical examination technology featuring FDA-cleared medical devices, announced the appointment of Adam Pellegrini as Chief Executive Officer alongside the closing of a $25 million-plus growth round led by Insig... |
| 14.07.2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension |
PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million.
>> Click here for more f... |
| 13.07.2026 | Indian startups raised over $131 million from July 06 to July 11, 2026; Iswarya tops the list | Between July 6 to July 11, 2026, as many as 21 Indian startups from diverse sectors raised over $132.11 million in funding from investors. That is 5% up week-on-week from $125.72 million logged the previous week, when Limelight Diamonds rai... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 09.07.2026 | Marico's acquired brands generate ₹2,375 crore in FY26 | Fast-moving consumer goods (FMCG) major Marico Ltd has assembled a sizeable portfolio of premium and digital brands through acquisitions over the past few years.
Detailed subsidiary financials released with the Parachute-maker's annual repo... |
| 09.07.2026 | IVF chain Iswarya snags funding from OrbiMed in maiden external round | Dr Arun Muthuvel, managing director, Iswarya
Iswarya Health Pvt Ltd, which operates a chain of in-vitro fertilization clinics under Iswarya Fertility Center, said Thursday it has secured Rs 350 crore (around $37 million) in growth investmen... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program
FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding.
The round was led by SR One, ... |
| 29.06.2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| 19.06.2026 | ETtech Deals Digest: Sarvam mega round lifts startup funding to $403 million this week, up 36% on-year | Synopsis
Indian startups secured a significant $402.6 million in funding across 20 deals, with AI firm Sarvam leading the pack with a $234 million investment. This marks a substantial increase from the previous week, highlighting robust inv... |
| 16.06.2026 | Nutrition brand TruNativ raises $30 million funding led by OrbiMed, eyes global expansion | - |
| 16.06.2026 | Nutrition band TruNativ raises $30M in Series B funding round led by OrbiMed | TruNativ, the Mumbai-based nutrition brand, has raised $30 million in a Series B round of funding led by OrbiMed, a healthcare focused investment firm.
The funding round comprised both primary investment and secondary transaction involving ... |
| 16.06.2026 | Nutrition brand TruNativ closes $30 million round with OrbiMed Advisors LLC | Synopsis
Clean-label nutrition brand TruNativ has secured $30 million from OrbiMed Advisors LLC to boost distribution, expand its product range, and establish a new R&D center. The Mumbai-based company, founded in 2019, aims to integrat... |
| 02.06.2026 | OrbiMed nears two-thirds mark for new Asia PE fund | Premium
Sunny Sharma, partner and senior managing director for Asia at OrbiMed | Credit: OrbiMed
Healthcare-focused private equity firm OrbiMed has collected close to two-thirds of the target corpus for its sixth Asia......
This is a Premiu... |
| 26.05.2026 | HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29 | TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced... |
| 19.05.2026 | Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases | Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza
Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis
NEW YORK and SUZH... |
| 19.05.2026 | Accro Bioscience: $50 Million Series C Raised To Advance Immune Mediated Disease Pipeline | Accro Bioscience announced the closing of a $50 million Series C financing round led by OrbiMed, with participation from TCG Crossover (TCGX), LAV, Cenova Capital, and existing investors Shenzhen Capital Group (SCGC) and Oriza Holdings.
The... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 29.04.2026 | Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million | Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors
SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biote... |
| 25.04.2026 | Pulnovo Medical: $100 Million Financing Round Led By Medtronic Closed | Pulnovo Medical, a New York-based pioneer in breakthrough therapies for pulmonary hypertension and heart failure, has completed an oversubscribed $100 million strategic financing round led by Medtronic, one of the world’s largest medical te... |
| 18.04.2026 | Terremoto Biosciences: $108 Million Series C Raised To Advance AKT1-Selective Oncology And Rare Disease Programs | Terremoto Biosciences, a clinical-stage biotechnology company focused on highly selective small molecule therapies, announced it has closed a $108 million Series C financing to advance its pipeline targeting cancer and rare diseases. The ro... |
| 15.04.2026 | Terremoto Biosciences Raises $108M in Series C Funding | Terremoto Biosciences, a San Francisco, CA-based biotechnology company developing highly targeted, small molecule medicines, raised $108M in Series C funding.
Backers included new investors RA Capital Management, Deep Track Capital, Osage U... |
| 08.04.2026 | Sidewinder Therapeutics: $137 Million Raised For Bispecific ADC Cancer Therapies | Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific antibody-drug conjugates, announced the closing of an oversubscribed $137 million Series B financing round to advance its oncology pipeline into clin... |
| 07.04.2026 | SpectronRx Raises $85M in Financing | SpectronRx, an Indianapolis, IN-based global radiopharmaceutical CDMO, CMO and isotope manufacturer, raised $85m in financing.
OrbiMed made the investment.
The company intends to use the funds to scale production capacity, enhance CDMO and ... |
| 03.04.2026 | China's BMI Frontier: StairMed Fuels Next-Gen Human-Machine Integration | StairMed secured RMB 500 million ($69M) from Alibaba, Tencent, and others. This investment accelerates brain-machine interface (BMI) and neuromodulation development. The company progresses 256-channel BMI clinical trials in China, pioneerin... |
| 02.04.2026 | StairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent | SHANGHAI, April 2, 2026 /PRNewswire/ -- Shanghai StairMed Technology Co., Ltd. ("StairMed" or "the Company") recently announced the closing of a strategic financing round totaling RMB 500 million. The round was led by Al... |
| 02.04.2026 | StairMed: RMB 500 Million (About $69 Million) Raised For Brain Machine Interface Development | Shanghai-based StairMed has secured RMB 500 million in a new financing round led by Alibaba, with participation from existing investors including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Vent... |
| 31.03.2026 | Congruence Therapeutics: $39.5 Million Secured To Advance Small Molecule Correctors Into Clinical Development | Congruence Therapeutics has announced the closing of a $39.5 million financing to support the advancement of its pipeline of small molecule correctors targeting diseases caused by protein misfolding. The financing round was co-led by Dimens... |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 26.03.2026 | Pinnacle Medicines Raises $89M in Series B Funding | Pinnacle Medicines, a Doylestown, PA-based biotechnology company developing oral peptide therapeutics, raised $89M in Series B funding.
The round was led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA... |
| 17.03.2026 | Venture Catalysts exits hygiene startup Pee Safe with 9.6x return after OrbiMed-led $32 million round | Synopsis
Other investors, including We Founder Circle, Alkemi Growth Capital and Alpha Capital, have also exited the company, Venture Catalysts founder Apoorva Ranjan Sharma told ET. Zerodha-backed Rainmatter and Natco Pharma continue to be... |
| 13.03.2026 | Alibaba leads RMB 500 million investment in BCI startup StairMed | StairMed, a brain-computer interface (BCI) developer, has secured RMB 500 million (USD 72.7 million) in a funding round led by Alibaba Group, with participation from SDIC Unity Capital. Existing investors including Tencent, FountainBridge C... |
| 01.02.2026 | Focus on biopharma comes at the right time: Industry | - |
| 30.01.2026 | ETtech Deals Digest: Startups raise $777 million in January so far; down 14% on-year | Synopsis
Startups across multiple stages raised the funds through 112 deals, compared to 210 in the year-ago period.
Listen to this article in summarized format
Listen
ETtech
Indian startups raised about $777.2 million in funding between Ja... |
| 25.01.2026 | Mendra Revolutionizes Rare Disease Therapy with $82M AI-Driven Launch | Mendra, a San Francisco biopharmaceutical firm, launched with an oversubscribed $82 million Series A funding round. This capital infusion propels its mission. Mendra focuses on rare disease therapies. The company leverages advanced AI. It t... |
| 23.01.2026 | Mendra Launched With $82 Million Series A To Build AI-Enabled Rare Disease Therapeutics Portfolio | Mendra, a newly launched biopharmaceutical company focused on rare diseases, has closed an oversubscribed $82 million Series A to acquire, develop, and commercialize therapies targeting high-unmet-need indications. The financing was co-led ... |
| 23.01.2026 | Mendra Raises $82M in Series A Funding | Mendra, a San Francisco, CA-based biopharmaceutical company developing therapies for rare disease medicines, raised $82M in Series A funding.
The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Win... |
| 16.01.2026 | ETtech Deals Digest: Startups raise $191 million this week, down 51% on-year | Synopsis
Indian startups raised about $190.7 million in mid-January, sharply lower than a year ago but well above the previous weekâs total. Funding activity also slowed, with fewer deals completed year on year. Healthcare, education and ... |
| 16.01.2026 | [Weekly funding roundup Jan 10-16] Sharp rise in VC inflow into Indian startups | The third week of January saw a sharp increase in venture capital funding into Indian startups, supported by a few reasonably sized deals. This comes as a relief to the ecosystem after the two preceding weeks saw lower amounts being raised.... |
| 15.01.2026 | Pee Safe Secures $32 Million to Propel Global Hygiene Market Expansion | Pee Safe, a prominent hygiene and wellness brand, recently closed a $32 million Series C funding round. Healthcare-focused private equity firm OrbiMed led this significant investment. The capital injection targets ambitious growth. It will ... |
| 15.01.2026 | Only two foreign investors remain on Vietnam-based The CrownX's cap table | - |
| 14.01.2026 | Mirador Therapeutics Secures $250M, Accelerates Precision Medicine | Mirador Therapeutics secured $250M in Series B funding. This propels their innovative precision medicine strategy. Total capital raised now exceeds $650M. The San Diego firm targets immune-mediated inflammatory and fibrotic diseases. Funds ... |
| 14.01.2026 | AirNexis Therapeutics Secures $200M for Groundbreaking COPD Treatment AN01 | AirNexis Therapeutics emerged, securing $200 million in Series A funding. This substantial capital infusion targets chronic obstructive pulmonary disease (COPD). The company focuses on developing AN01, a novel dual PDE3/4 inhibitor. AN01 is... |
| 14.01.2026 | Wellness brand Pee Safe closes a $32 million funding round with OrbiMed | Synopsis
Pee Safe has closed a $32 million round with OrbiMed, a global healthcare-focused private equity firm. The company plans to deploy the capital to scale its offline retail presence, strengthen marketing efforts, and deepen its reach... |
| 14.01.2026 | Pee Safe raises funding from OrbiMed to scale retail, quick-commerce push | Pee Safe co-founders (from left) Vikas Bagaria and Rithish Kumar
Hygiene and wellness brand Pee Safe has secured capital in a growth funding round from healthcare-focused private equity firm OrbiMed, as it looks to expand its retail and qui... |
| 14.01.2026 | Femtech Brand Pee Safe Bags $32 Mn From OrbiMed | SUMMARY
Pee Safe has secured $32 Mn (INR 290 Cr) in its Series C round from Netmeds-backer OrbiMed in a mix of primary and secondary share sale
In addition to the capital infusion, OrbiMed’s Dr Sunny Sharma and Sumona Chakraborty will join ... |
| 14.01.2026 | Pee Safe raises $32M from OrbiMed to scale women’s hygiene business | Pee Safe, the Gurugram-based women’s hygiene and wellness startup best known for popularising toilet seat sanitiser sprays in India, has raised $32 million (around Rs 290 crore) in a Series C funding round led by OrbiMed.
The round includes... |
| 14.01.2026 | Pee Safe raises $32 million from OrbiMed to accelerate expansion | - |
| 13.01.2026 | Mirador Raises $250M in Series B Funding | Mirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding.
Backers included T. Rowe Price Investme... |
| 12.01.2026 | Qiming-backed biotech Oricell raises $70m Series C1 round | - |
| 12.01.2026 | Mirador Therapeutics: $250 Million Series B Raised And Multi-Asset Immuno-Fibrotic Pipeline Advanced | Mirador Therapeutics announced it is advancing multiple clinical-stage programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis, with more than 10 clinical readouts expected by the end of ... |
| 12.01.2026 | Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion | HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities
BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticke... |
| 11.01.2026 | AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD | AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license to a Phase 2 dual PDE3/4 inhibitor for chronic obstructive pulm... |
| 31.12.2025 | Biobeat: $50 Million Series B Secured To Expand Commercialization Of Cuff-Less 24-Hour Blood Pressure Monitoring | Biobeat Technologies announced it has closed a $50 million Series B equity financing to accelerate the commercialization of its FDA-cleared, cuff-less 24-hour ambulatory blood pressure monitoring (ABPM) system in the United States.
The roun... |
| 16.12.2025 | BlossomHill Therapeutics Raises $84M in Series B Extension Funding | BlossomHill Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $84M in Series B extension funding.
The round was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participati... |
| 06.11.2025 | Braveheart Bio Launches With $185 Million Series A To Advance Treatment For Hypertrophic Cardiomyopathy | Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A financing. The investment was led by Andreessen ... |
| 05.11.2025 | Braveheart Bio Raises $185M in Series A Funding | Braveheart Bio, a San Francisco, CA-based clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, raised $185M in Series A financing.
Backers included Andreessen Horow... |
| 23.10.2025 | Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer | Electra Therapeutics, a clinical-stage biotechnology company pioneering therapies against novel targets in immunology and cancer, has announced the close of an oversubscribed $183 million Series C financing round. The round was co-led by Ne... |
| 22.10.2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing.
The round was co-led by Nextech... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 09.10.2025 | AirStrip Secures $50M Growth Credit Commitment and Additional Equity Investment from OrbiMed | Airstrip, a San Antonio, TX-based enterprise AI healthcare technology company, raised $50M in credit facility with OrbiMed.
OrbiMed also made a preferred stock investment in AirStrip.
The amount of the deal was not disclosed.
The company in... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 01.10.2025 | Expert Systems: Series A Funding Raised For Drug Discovery Platform | Expert Systems, a leading provider in drug discovery acceleration, has recently announced a Series A funding round and the launch of Mondego Bio, an innovative company focused on immuno-oncology. Mondego Bio is headquartered in Biocant Park... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding.
The round was co-led by Sanofi Ventures and Vi... |
| 29.09.2025 | Kapiva Secures USD 60 Mn in Series D Funding to Boost Growth The Series D funding round was led by 360 ONE Asset and Vertex Growth, with participation from existing backers Vertex Ventures Southeast A... | Ayurveda wellness brand Kapiva has raised USD 60 million in a Series D funding round led by 360 ONE Asset and Vertex Growth, with participation from existing backers Vertex Ventures Southeast Asia and India and 3one4 Capital.
Of the total, ... |
| 29.09.2025 | Ayurvedic wellness brand Kapiva raises Series D funding | Kapiva's co-founders
Ayurvedic wellness brand Kapiva has raised $60 million (Rs 510 crore) in a Series D funding round led by homegrown investor 360 ONE Asset and Singapore-based Vertex Growth fund, a top executive told VCCircle.
Existing i... |
| 27.09.2025 | Sparrow Pharmaceuticals: $95 Million Series B Raised For Advancing Targeted Therapy For Type 2 Diabetes | Sparrow Pharmaceuticals, a company focused on developing therapies for cardiometabolic conditions, recently announced the successful completion of a Series B financing round, raising an impressive $95 million. This significant investment wa... |
| 24.09.2025 | Sparrow Pharmaceuticals Raises $95M in Series B Financing | Sparrow Pharmaceuticals, a Portland, OR-based cardiometabolic therapeutics company, raised $95M Series B financing.
The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, Rive... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding.
The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 12.09.2025 | Congruence Therapeutics: $32 Million Financing Raised For Advancing Genetic Obesity Therapy | Congruence Therapeutics has secured a $32 million financing round to support the development of its lead candidate CGX-926, the first clinical therapy designed to treat MC4R-deficient genetic obesity. The proceeds will fund a Phase 1 trial ... |
| 08.09.2025 | Epigenic Therapeutics Closes $60M Series B Financing | Epigenic Therapeutics, a Shanghai, China-based clinical-stage drug development company, raised $60M in Series B funding.
The round was led by Lapam Capital, with participation from existing investors Qiming Venture Partners and OrbiMed, and... |
| 08.09.2025 | Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines | SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, wi... |
| 07.09.2025 | Charm Therapeutics Secures $80M for AI-Driven Cancer Battle | Charm Therapeutics, a London-based biotech firm, clinched $80M in Series B funding. This investment fuels its AI-driven drug discovery platform. The company targets precision oncology, focusing on acute myeloid leukemia (AML). Its lead meni... |
| 05.09.2025 | China's Hengrui Rises After Granting Braveheart Bio Heart Drug Rights in Up to USD1.1 Billion Deal | (Yicai) Sept. 5 -- Shares of Hengrui Pharmaceuticals rose after the drugmaker granted US' Braveheart Bio the exclusive global rights outside of China to an innovative heart drug in a deal worth as much as USD1.1 billion, the Chinese firm's ... |
| 03.09.2025 | Treeline Biosciences: $200 Million Additional Funding Raised And First Clinical Trials Announced | Treeline Biosciences, a company at the forefront of innovative cancer research, recently announced significant progress in its clinical development. They have started Phase 1 trials for three promising programs, two of which are internally ... |
| 02.09.2025 | London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers | British BioTech startup CHARM Therapeutics, announces closing of an oversubscribed Series B funding round, raising €68.5 million to advance its next generation menin inhibitor into clinical development.
The funding round was co-led by New E... |
| 02.09.2025 | Charm Therapeutics Raises $80M in Series B Financing | Charm Therapeutics, a London, UK-based biotechnology company which specializes in precision oncology treatments, raised $80M in Series B funding.
The round was led by New Enterprise Associates (NEA) and SR One, with participation from exist... |
| 02.09.2025 | ProVerum: $80 Million Series B Raised For Advancing BPH Treatments | ProVerum Limited is a company that has made significant strides with its development of the ProVee System, a minimally invasive solution specifically designed for treating benign prostatic hyperplasia (BPH). Recently, the company announced ... |
| 30.08.2025 | Leal Therapeutics: $30 Million Series A Secured To Advance Breakthrough CNS Therapies | Leal Therapeutics, a biotechnology company pioneering novel treatments for central nervous system (CNS) disorders, has announced the closing of a $30 million Series A financing round. The round was led by SV Health Investors’ Dementia Disco... |
| 27.08.2025 | Leal Therapeutics Raises $30M in Series A Funding | Leal Therapeutics, a Worcester, MA-based biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), raised $30M in Series A funding.
The round was led by SV Health Investors’ Dementi... |
| 26.08.2025 | Irish MedTech startup ProVerum raises €68.6 million to advance new treatment for urological conditions | ProVerum, a MedTech startup based in Dublin, has secured €68.6 million in Series B equity financing to advance the commercialisation of its minimally invasive solution for benign prostatic hyperplasia (BPH).
The round was led by MVM Partner... |
| 25.08.2025 | ProVerum: $80 Million Series B Raised For Treating BPH | ProVerum Limited, a leading innovator in urological medical devices, has announced the successful completion of an $80 million Series B equity financing round. This significant capital raise is a major milestone for the company as it moves ... |
| 11.08.2025 | Minghui Pharmaceutical Raises USD 131M in Pre-IPO Financing | Minghui Pharmaceutical, a Singapore-based clinical biopharmaceutical company, raised USD 131M Pre-IPO financing.
The round was led by new investors OrbiMed and co-led by Qiming Venture Partners with participation from existing investor TF C... |
| 10.08.2025 | OrbiMed, Qiming lead $131m pre-IPO financing for late-stage clinical biopharma Minghui | Global healthcare investment firm OrbiMed and Qiming Venture Partners have jointly led a pre-IPO financing of $131 million in Minghui Pharmaceutical, a Chinese late-stage clinical biopharmaceutical company, according to a statement.
Shangha... |
| 07.08.2025 | OrbiMed: $1.86 Billion Raised For Healthcare Royalty & Credit Fund V | OrbiMed, a leading global healthcare investment firm, has raised $1.86 billion for the OrbiMed Royalty and Credit Opportunities Fund V.
This fund will provide tailored investment solutions, focusing on non-dilutive credit and royalty-based ... |
| 07.08.2025 | Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion | SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led... |
| 18.07.2025 | $50 million to scale drill-free dental treatments |
Today, tooth decay remains the number one non-communicable disease in the world, according to the World Health Organization. vVARDIS founders Haley and Goly Abivardi address this epidemic with groundbreaking biomimetic, non-invasive soluti... |
| 10.07.2025 | Renasant Bio Raises $54.5M in Seed Funding | Renasant Bio, a Berkeley, CA-based developer of disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), raised $54.5M in Seed funding.
The round was led by 5AM Ventures, alongside other life sciences investors... |
| 23.06.2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 12.06.2025 | OrbiMed scores high returns from four-year-old India bet | Pro
Sunny Sharma, partner and senior managing director for Asia at OrbiMed | Credit: OrbiMed
Healthcare-focused private equity firm OrbiMed has made its second monetisation move of the year from its India portfolio as it trimmed its stake i... |
| 02.06.2025 | OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovar... | CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity
CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs
Promising signs of efficacy were observed in patie... |